VanEck Associates
GNMX

VanEck Associates’s Aevi Genomic Medicine Inc GNMX Stock Holding History

VanEck Associates’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-17,054
Closed -$21K – 731
2017
Q3 		$21K Buy
17,054
+761
+5% +$972 ﹤0.01% 722
2017
Q2 		$22K Buy
16,293
+1,846
+13% +$2.67K ﹤0.01% 731
2017
Q1 		$27K Hold
14,447
– – ﹤0.01% 867
2016
Q4 		$75K Sell
14,447
-1,299
-8% -$6.83K ﹤0.01% 757
2016
Q3 		$88K Buy
15,746
+58
+0.4% +$331 ﹤0.01% 732
2016
Q2 		$87K Sell
15,688
-4,295
-21% -$22.6K ﹤0.01% 702
2016
Q1 		$88K Buy
19,983
+115
+0.6% +$473 ﹤0.01% 687
2015
Q4 		$120K Buy
19,868
+2,279
+13% +$15.5K ﹤0.01% 605
2015
Q3 		$138K Buy
17,589
+2,248
+15% +$17.4K ﹤0.01% 597
2015
Q2 		$94K Sell
15,341
-1,520
-9% -$11.8K ﹤0.01% 657
2015
Q1 		$136K Sell
16,861
-1,206
-7% -$9.1K ﹤0.01% 623
2014
Q4 		$91K Buy
18,067
+3,198
+22% +$15.8K ﹤0.01% 648
2014
Q3 		$77K Buy
14,869
+1,382
+10% +$8.92K ﹤0.01% 662
2014
Q2 		$105K Buy
13,487
+2,363
+21% +$16.7K ﹤0.01% 677
2014
Q1 		$78K Buy
11,124
+2,308
+26% +$18K ﹤0.01% 667
2013
Q4 		$53K Buy
+8,816
New +$57.7K ﹤0.01% 664

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

VanEck Associates's GNMX Position: Q4 2017 in Review

VanEck Associates sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2017, closing a stake of 17,054 shares — an estimated $21K sold.

VanEck Associates first reported a position in GNMX in Q4 2013 and held it in 16 quarters. The position peaked at $138K in Q3 2015. 45 funds tracked by Wall St. Rank hold GNMX as of Q4 2017.

  • VanEck Associates reported no remaining Aevi Genomic Medicine Inc position as of Q4 2017 after selling out during the quarter.
  • VanEck Associates sold 17,054 Aevi Genomic Medicine Inc shares in Q4 2017, an estimated $21K.
  • VanEck Associates first reported a position in Aevi Genomic Medicine Inc in Q4 2013 and held it in 16 quarters.
  • VanEck Associates's Aevi Genomic Medicine Inc position peaked at $138K in Q3 2015.
  • 45 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2017.

Based on VanEck Associates's 13F filing for Q4 2017, filed 12 Feb 2018.